13F Holdings
中文EN

CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1187953 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY-25.4%
TTM EPS YoY29.9%
Revenue 3-yr CAGR-50.4%
Net income 3-yr CAGR—

Margins

Gross margin66.9%
Operating margin-256,435.0%
Net margin-249,160.1%
FCF margin—
EBITDA margin—

Returns

ROE-119.2%
ROA-113.8%
ROIC (approx.)-3,736.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.0%
Debt / equity0.00x
Current ratio23.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-16.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6,000$11,000$9,000$88,600$87,754
Cost of revenue$2,194$4,400$3,600$28,491$47,949
Gross profit$3,806$6,600$5,400$60,109$39,805
R&D expense$2.26M$2.40M$1.97M$6.27M$109,180
SG&A expense$3.76M$3.24M$3.56M$3.94M$2.96M
Operating income-$6.14M-$5.74M-$5.62M-$10.24M-$3.13M
Interest expense———$0$4.28M
Pretax income-$6.00M-$5.49M-$5.29M-$10.14M$19.21M
Income tax$0$0$0$0$0
Net income-$6.00M-$5.49M-$5.29M-$10.14M$19.21M
EBITDA—-$5.69M-$5.56M——
EPS (basic)———-0.937.37
EPS (diluted)-2.52-3.71-3.76-0.935.61
Weighted avg. shares (diluted)2.38M1.48M1.41M10.93M3.25M
Balance sheet
Cash & equivalents$7.21M$5.94M$3.47M$8.32M$10.72M
Receivables———$0$2,485
Inventory$0$2,194$6,594$10,194$10,866
Current assets$7.40M$6.14M$10.27M$18.75M$10.74M
Intangibles$407,230$530,559$441,011$435,595$527,679
Total assets$7.81M$6.67M$10.72M$19.19M$11.27M
Current liabilities$284,880$327,644$371,394$3.32M$1.05M
Total liabilities$284,880$327,644$371,394$3.32M$1.05M
Shareholders' equity$7.51M$6.34M$10.34M$15.86M$10.22M
Shares outstanding3.70M1.75M1.37M1.41M6.34M
Cash flow statement
Operating cash flow-$5.86M-$5.30M-$8.03M-$7.80M-$2.22M
Investing cash flow-$50,500$6.32M$3.45M-$10.08M$0
Financing cash flow$7.17M$1.45M-$270,952$15.47M$12.84M
Depreciation & amortization—$56,000$56,000——
Stock-based compensation$3,485$36,648$36,648$68,746$595,380
Share buybacks$10,000$174,964$270,952$0—

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.